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THE ‘‘SIDE-POPULATION’’ OF HUMAN LYMPHOMA CELLS HAVE IN-
CREASED CHEMO-RESISTANCE, STEM-CELL LIKE PROPERTIES AND
ARE POTENTIAL TARGETS FOR IMMUNOTHERAPY
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We have previously demonstrated that hematological malignan-
cies contain a distinct ‘‘side-population’’ (SP), which is character-
ized by the active transport of Hoechst fluorescent dye. The
mechanisms responsible for Hoechst efflux contribute to SP resis-
tance to chemotherapy and SP have been shown to be enriched for
tumor initiating cells in several human cancer models. We hypoth-
esize that targeting the cancer ‘‘SP’’ cells using immunotherapy may
prevent relapse by eliminating the cell population that is chemore-
sistant and has tumor repopulating potential. We characterized SP
cells in 11 human lymphoma cell lines. 5/11 lymphoma cell lines
had a distinct SP ranging from 0.8–2% of total cells. We subse-
quently found SP cells with tumor associated antigens (TAAs) in
biopsy samples from patients with Hodgkin’s Lymphoma, T-cell
Lymphoma, and Follicular lymphoma. Culture of the sorted cell
lines show that SP but not the non-SP cells produced progeny
that were both SP and non-SP cells. Gene expression analysis of
the SP showed increased expression of ABC transporters that me-
diate transport of some chemotherapeutic agents out of the cell.
We evaluated whether lymphoma cell lines with a SP are resistant
to the chemotherapeutic drug gemcitabine. The viability of lym-
phoma lines containing SP cells was markedly higher (mean
59.8%; range 37.4–87.8) than the viability of lines without a SP
(mean 9.3% range 3.0%–12.2) when cultured with 10nM gemcita-
bine for 3 days. The SP component of the lymphoma cells became
enriched 10-fold when cultured with gemcitabine. Moreover, when
equal numbers of SP and non-SP cells were grown in separate frac-
tions with gemcitabine, there was reduced viability of the non-SP
(mean 2,2476 294 cpm) by thymidine assay. In contrast, the viabil-
ity of the SP was preserved (mean 13,200 6 7500 cpm). Although
lymphoma SP cells are resistant to chemotherapeutic agents, they
also express higher levels of TAAs that are known targets for cyto-
toxic T-cells. RT-PCR and immunohistochemistry both show that
SP cells are HLA positive and have increased expression of TAAs
(e.g. MAGEA, SSX, PRAME) transcripts and protein compared
to non-SP cells from the same tumor. We have generated T-cells
that recognize these TAAs and have shown they can recognize
and kill SP targets. Hence, lymphoma cell lines and primary lym-
phoma tissue contain chemotherapy-resistant SP cells which
express tumor associated antigens and may be targeted by specific
T cells.180
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AND NON-HODGKIN’S LYMPHOMA
Gutierrez-Aguirre, C.H.1, Cantu-Rodriguez, O.G.1, Gonzalez-
Llano, O.1, Jaime-Perez, J.C.1, Salazar-Riojas, R.1, Martinez-
Gonzalez, O.L.1, Gutierrez-Riverol, K.I.2, Ruiz-Delgado, G.J.2,
Ruiz-Arguelles, G.J.2, Gomez-Almaguer, D.1 1Hospital Universitario
de La U.A.N.L., Monterrey, Nuevo Leon, Mexico; 2Centro de Hematolo-
gia y Medicina Interna de Puebla, Puebla, Mexico
Introduction: The role of reduced-intensity conditioning alloge-
neic stem cell transplantation (allo- RICSCT) compared with high-
dose chemotherapy followed by autologous stem cell transplantation
(auto-SCT) in Hodgkin’s disease (HD) and in non Hodgkin’s lym-
phoma (NHL) patients remains poorly defined. We retrospectively
analyzed the outcome of 71 patients with advanced disease who re-
ceived one of both treatments, 39 patients with NHL and 32 with
HD. Twenty three NHL patients and 14 HD patients received an
allo-RICSCT using fludarabine-cyclophosphamide-low dose busul-
fan as conditioning regimen. Sixteen NHL patients and 18 HD pa-
tients received auto-SCT using cyclophosphamide and etoposide as
conditioning regimen.
Results: (see table 1).Table 1
NHL 1 Allo NHL 1 Auto HD 1 Allo HD 1 AutoAge (median) years 47 56 26 26
Disease stage
before SCT
1st remission 0 7 (44%) 1 (7%) 3 (17%)
2nd remission 8 (35%) 2 (12%) 0 3 (17%)
Refractory 16 (65%) 7 (44%) 13 (93%) 12 (66%)
Ann Arbor I-II 5 (22%) 7 (44%) 0 6 (33%)
Ann Arbor III-IV 18 (78%) 9 (56%) 14 (100%) 12 (67%)
B symptoms 65% 75% 85% 89%
CD341 cells
infused5  106 2.2  106 4.5  106 3  106aEICH / cEICH 39% / 31% — 14% / 7% —
Overall survival 69% 81% 36% 65%
Death 7 (31%) 3 (19%) 9 (64%) 7 (35%)
Relapse 4 (17%) 5 (31%) 7 (50%) 11 (61%)
Relapse as cause
of death3(42%) 1(33%) 7 (78%) 7 (100%)n5 23 16 14 18Characteristics of the patients included and results. Conclutions:
We found significant difference in overall survival between allo-
RICSCT recipients and auto-SCT recipients and also a higher
mortality in HD patients and in NHL patients who received an
allo-RICSCT. The relapse rate was higher in autografted patients,
both in NHL an HD, even in patients in first remission. We con-
clude that both therapeutic modalities may be useful in refractory
NHL patients and seems that in refractory HD the results were
better using autologous grafts.181
PRE-MOBILIZATION BONE MARROW PLASMACYTOSIS PREDICTS
SUCCESSFUL STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE
MYELOMA RECEIVING LENALIDOMIDE-BASED INDUCTION REGIMENS
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High-dose chemotherapy (HDC) with autologous stem cell trans-
plant (ASCT) remains a crucial therapeutic option for many patients
with multiple myeloma (MM). Although thalidomide, lenalidomide
and bortezomib may be associated with improved outcomes
compared with traditional therapies, how to best integrate novel
agents into a treatment plan incorporating HDC/ASCT remains
unknown. Moreover, recent studies have suggested that the use of
lenalidomide, in particular, may impair subsequent ability to harvest
stem cells for ASCT. We examined our institutional experience in
287 sequential patients with MM who underwent HDC/ASCT
from 1992 to 2008 stratified by the type of induction regimen re-
ceived prior to HDC/ASCT: chemotherapy-based (e.g., VAD,
DVD) or novel agent-based (thalidomide, lenalidomide, or bortezo-
mib). Patients were similar in age, Durie Salmon and ISS stage,
high-risk karyotype/FISH status, and other variables. Time from di-
agnosis to mobilization was similar and no differences were seen in
remission status at time of stem cell mobilization. However, success-
fully mobilized patients who received induction regimens containing
a novel agent had lower pre-mobilization marrow plasmacytosis
(mean 12.9% 6 SD 16) than patients who received chemotherapy-
based inductions (mean 22%6 27, p5 0.001), yet total marrow cel-
lularity was similar between groups. Controlling for other variables
(e.g., use of cyclophosphamide for mobilization and prior radiation
exposure), pre-mobilization marrow plasmacytosis predicted the
chances of successful stem cell mobilization in patients who received
induction with lenalidomide: successfully mobilized patients had less
marrow plasma cells pre-mobilization (5% 6 8) than patients who
failed mobilization (21% 6 1.2, Table 1, p 5 0.001). Patients with
prior lenalidomide or bortezomib exposure collected fewer
CD34(1) stem cells than patients receiving chemotherapy or thalid-
omide based inductions (p 5 0.0001). Patients who received prior
lenalidomide also engrafted slower than patients who received other
induction regimens following HDC/ASCT, independent of
